Persistent effect of tocilizumab in refractory Takayasu’s arteritis (clinical observation)
Open Access
- 14 May 2022
- journal article
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (2), 242-248
- https://doi.org/10.47360/1995-4484-2022-242-248
Abstract
Study of the interleukin 6 (IL-6) role in chronic autoimmune inflammation has led to the development of innovative treatments for various autoimmune inflammatory rheumatic diseases, including Takayasu’s arteritis (TAK). Given the important role of IL-6 in the pathogenesis of TAK and its association with high clinical and laboratory activity of the disease, tocilizumab (TCZ) is recommended as a second-line drug if both glucocorticoids and basic antiinflammatory drugs are inefficient, and previous therapy with tumor necrosis factor-α (alpha) inhibitors. The article presents our own observation of the successful use of TCZ in a patient with refractory TAK.Keywords
This publication has 33 references indexed in Scilit:
- Takayasu arteritis revisited: Current diagnosis and treatmentInternational Journal of Cardiology, 2013
- Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long‐term followupArthritis Care & Research, 2012
- Takayasu arteritis in children and adolescentsRheumatology, 2010
- The epidemiology of Takayasu arteritis in the UKRheumatology, 2009
- Successful treatment of a patient with takayasu arteritis using a humanized anti–interleukin‐6 receptor antibodyArthritis & Rheumatism, 2008
- Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritisClinical Rheumatology, 2007
- Limitations of therapy and a guarded prognosis in an american cohort of takayasu arteritis patientsArthritis & Rheumatism, 2007
- Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritisRheumatology, 2005
- Diagnostic criteria for Takayasu arteritisInternational Journal of Cardiology, 1996
- Takayasu ArteritisMedicine, 1985